Sees FY23 adjusted EBITDA loss $31M-$36M. The company said, "We will remain focused on the key initiatives that we outlined at the beginning of 2023: (1) advancing AQST-109 into a pivotal PK study, (2) continuing to work with the FDA to potentially accelerate the U.S. market access for Libervant, (3) exploring new capabilities for our manufacturing business, (4) continuing to expand our base of strategic collaborations with other companies, and (5) strengthening our balance sheet."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AQST:
- Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
- Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
- Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
- Aquestive Therapeutics downgraded to Neutral from Outperform at Wedbush
